THERAPY DOSSIER · th-fbc9563b3527

Tendon-derived hydrogel with systemically delivered adipose-derived stem cells

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32605739 ↗2020Mixed findings

Homing of Adipose-Derived Stem Cells to a Tendon-Derived Hydrogel: A Potential Mechanism for Improved Tendon-Bone Interface and Tendon Healing.

RatWoundLocal hydrogel application to the injury site or subcutaneous injection; labelled adipose-derived stem cells by tail vein injectionHydrogel or saline at the time of injury; labelled stem cells by tail vein 1 we…

Model: Acute tendon injury and chronic tendon-bone interface injury models, plus a subcutaneous injection model

Systemically delivered adipose-derived stem cells homed to acute tendon and chronic tendon-bone interface injuries and to the tendon-derived hydrogel, but there was no difference in macrophage number, cell proliferation or angiogenesis one week after delivery.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…